Abstract. The miR-200 family was recently identified as a suppressor of epithelial-mesenchymal transition (EMT). The loss or gain of miR-200 family members is associated with cancer invasion. The epidermal growth factor receptor (EGFR) is overexpressed in the majority of anaplastic thyroid cancers (ATCs). The activation of EGFR by its ligand, epidermal growth factor (EGF), activates a signaling cascade that results in the enhanced migration and invasiveness of thyroid cancer cells. However, little is known about the potential interrelationships between EGF/EGFR, miR-200s and the induction of EMT or mesenchymal-epithelial transition (MET) processes. This study aimed to investigate the regulatory role of miR200s in EMT modulation by EGF/EGFR. Using transfection, real-time reverse transcription PCR and western blot analysis, we found that the EGF treatment of Nthy-ori 3-1 thyroid follicular cells resulted in the downregulation of E-cadherin and the upregulation of vimentin. By contrast, EGFR silencing in SW1736 human thyroid carcinoma cells led to the upregulation of E-cadherin and the downregulation of vimentin. In addition, EGF signaling correlated with the reduced expression of miR-200s and the re-expression of miR-200s abrogated the effects of EGF treatment and restored an epithelial phenotype to EGF-induced Nthy-ori 3-1 cells. Conversely, the silencing of miR-200s in SW1736 cells overcame siEGFR-induced changes in gene expression and phenotype. In addition, we demonstrate that miR-200s play a key role in in vitro EGF/EGFR-mediated thyroid cell invasion and in EMT in vivo. We, therefore, provide a mechanistic link between the miR-200 family and EGF/EGFR, which suggests that miR-200 upregulation may serve as a novel therapeutic strategy for highly invasive thyroid cancers.
Introduction
Anaplastic thyroid cancer (ATC) is one of the most aggressive types of malignant tumor, characterized by invasion into surrounding tissues and metastasis that contribute to a poor prognosis for patients with this disease (1) (2) (3) . The acquisition of invasive and migratory properties is associated with epithelialmesenchymal transition (EMT) and is a prerequisite for cancer invasion into surrounding tissues, the first stage of metastatic disease (4) (5) (6) .
The epidermal growth factor receptor (EGFR), a transmembrane cell-surface glycoprotein with intrinsic tyrosine kinase activity, is overexpressed in most ATCs (7) . EGFR activation by its ligand, the epidermal growth factor (EGF), initiates a signaling cascade that results in changes in gene expression. EGF is the prototype of a large family of structurally related peptides that possess an EGF-like domain, consisting of 6 cysteine residues capable of forming 3 intramolecular loops stabilized by disulfide bonds. EGF is synthesized by the thyroid gland and can induce thyroid cell proliferation in a number of species. In addition, EGF enhances the migration and invasiveness of thyroid cancer (3, (8) (9) (10) (11) .
The Rho/Rho kinase pathway may be important for cancer invasion, growth and metastasis. In vitro studies and animal experiments have suggested that the inhibition of the Rho/Rho kinase pathway inhibits tumor invasion and metastasis (12) (13) (14) (15) (16) . Zhong et al (3) demonstrated that lovastatin suppresses the invasive capability of ATC cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Rho/ ROCK signaling is required for EGF-induced invasion of ARO human ATC cells.
The expression of miR-200s is associated with tumor invasion and regulates EMT in cancer cells (17) (18) (19) (20) . However, nothing is known about interrelationships between EGF/ EGFR, miR-200s and the EMT or mesenchymal-epithelial transition (MET) processes. In the current study, we first show that the activation of EGF/EGFR signaling by EGF treat-ment of Nthy-ori 3-1 thyroid follicular cells downregulates E-cadherin with a concomitant upregulation of vimentin. Conversely, the downregulation of EGF/EGFR signaling by EGFR silencing in SW1736 cells results in E-cadherin upregulation and vimentin downregulation. Secondly, EGF treatment inversely correlates with the expression of miR-200 family members. Thirdly, re-expression of miR-200s in EGF-induced Nthy-ori 3-1 cells restores an epithelial phenotype, whereas the silencing of miR-200s in SW1736 cells reverses siEGFRmediated changes. Finally, miR-200s are shown to play a key role in EGF/EGFR-mediated thyroid cell invasion in vitro and EMT in vivo, suggesting that EGF/EGFR signaling regulates the aggressiveness of SW1736 cells by modulating miR-200 expression.
Materials and methods
Cell lines and reagents. The Nthy-ori 3-1 normal thyroid follicular epithelial cell line and the SW1736 human and ARO human ATC cell lines were obtained from the State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences (Beijing, China). All cells were cultured in RPMI-1640 medium supplemented with 5% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin in a humidified atmosphere with 5% CO 2 at 37˚C. All cell lines were tested and authenticated by short tandem repeat profiling using the PowerPlex 16 System (Promega). Antibodies were obtained from the following suppliers: vimentin (Abcam); E-cadherin, RhoA and β-actin (Sigma).
Real-time reverse transcription PCR (RT-PCR).
Total RNA was isolated using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Real-time PCR was used to quantify mRNA expression. Primer sequences for E-cadherin, vimentin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were as described previously (21) , and specific gene expression was normalized to GAPDH. For miRNA analysis, total RNA was isolated using the mirVana miRNA isolation kit (Ambion) and the levels of miRNAs were determined using miRNA-specific TaqMan MGB probes from the TaqMan MicroRNA assay kit (Applied Biosystems). miRNA expression was normalized to RNU6B (Sigma).
Transfection experiments. Thyroid cells were seeded into 12-well plates and subjected to transfection with specific siRNAs targeting EGFR, pre-miR-200s (miR-200a, miR-200b and miR-200c), anti-miR-200s (Sigma), or scrambled controls by the liposome method, as described previously (8) .
Western blot analysis. Western blot analyses were performed as previously described (9) . Briefly, proteins were electrophoresed on 12% polyacrylamide gels and transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (Amersham). Western blot analysis was carried out with specific primary antibodies diluted in 1% bovine serum albumin (BSA) in TBST, followed by peroxidase-conjugated secondary antibody. Target proteins were observed using the enhanced chemiluminescence (ECL) detection system (GE Healthcare) and autoradiography on Fuji super RX film (Fuji, Tokyo, Japan), with 1-2 min exposure.
Cell invasion assay. Cell invasion through a reconstituted Matrigel basement membrane was assayed as previously described (22) . Briefly, polycarbonate membranes (8.0 mm pore size) in the base of the upper compartment of Transwell culture chambers were coated with 10% Matrigel (50 µl/insert), and the lower compartment was filled with 600 µl serum-free medium containing 0.1% BSA. Cells were suspended in serum-free medium and seeded into the Transwell inserts. After 24 h, cells that had invaded the Matrigel membrane were stained with 4 mg/ml calcein AM (Invitrogen) in PBS at 37˚C for 1 h and then photographed under a fluorescent microscope. Invading cells were then trypsinized to remove them from the inserts. The images were recorded and analyzed using a Zeiss confocal photomicroscope LSM510 (Zeiss).
Immunohistochemistry. Immunohistochemistry analysis was performed as previously described (23) . Paraffin-embedded tissues were cut into 4 µm thick sections. Endogenous peroxidase activity was then blocked with 3% hydrogen peroxide, and then endogenous biotin was blocked with 0.01% avidin. Following blocking for 1 h with 3% BSA, the sections were incubated with anti-E-cadherin (1:50) or anti-vimentin (1:100) antibody for 1 h at room temperature. Immunoreactivity was detected using the biotin-streptavidin-peroxidase complex method and visualized using the 3,3'-diaminobenzidine (DAB; Dako) chromogen. Sections were counterstained with hematoxylin.
A modified semi-quantitative scoring system (23,24) was used to evaluate immunostaining by light microscopy: 0, no cells stained in any field; 1, positive staining of <25% of cells; 2, positive staining of 25-50% of cells; 3, positive staining of 50-75% cells; and 4, positive staining of >75% cells. Staining intensity was evaluated using the following scale: 0, no cell staining; 1+, mild staining; 2+, moderate staining; and 3+, strong staining. The total score was generated by adding the scores for the percentage of positive cells and staining intensity together.
Animal experiments. Six-week-old athymic nude mice (nu/nu), obtained from the Chinese Academy of Medical Sciences, were allowed to adapt to the laboratory environment for 1 week. Experiments were then performed as previously described (25) . Briefly, SW1736 cells transfected with either scrambled siRNA or EGFR-specific siRNA (EGFR-silenced cells) were injected through the tail vein of female mice. In order to examine the effect of anti-miR-200s in vivo, EGFR-silenced SW1736 cells were also injected into the mice. SW1736 cells (3x10 6 cells/animal) were immobilized in Matrigel (300 mg/ml) and injected into the mice. Ten mice were included in each treatment group. After 4 weeks, all mice were sacrificed and tumor tissue was removed and processed for immunohistochemistry. All procedures were monitored and approved by the local ethics committee and federal authorities and were conducted in accordance with the guidelines for the welfare of animals in experimental neoplasia.
Statistical analysis. Differences between groups were analyzed by one-way ANOVA using SPSS13.0 software (SPSS, Chicago, IL, USA). P-values <0.05 were considered to indicate statistically significant differences.
Results

EGF/EGFR signaling correlates with vimentin, E-cadherin
and RhoA expression. The induction of the EGF/EGFR pathway by the EGF treatment of Nthy-ori 3-1 cells resulted in the upregulation of the mesenchymal marker, vimentin, accompanied by the reduced expression of the epithelial marker, E-cadherin, suggesting the induction of an EMT phenotype. By contrast, the downregulation of EGF/EGFR signaling by siRNA-mediated EGFR silencing in SW1736 cells resulted in increased E-cadherin mRNA expression, concomitant with the reduced vimentin expression. To rule out cell line-specific effects, we carried out similar studies using the aggressive thyroid cancer cell line, ARO, and also found that EGFR silencing resulted in a significant increase in E-cadherin mRNA levels and decreased vimentin expression (Fig. 1) . We evaluated RhoA expression by western blot analysis, and found that the EGF treatment of Nthy-ori 3-1 cells led to increased RhoA expression, whereas EGFR silencing in SW1736 and ARO cells led to the downregulation of RhoA (Fig. 2) . As EGFR silencing 
EGF induces downregulation of miR-200s and EMT is reversed by re-expression of miR-200s in Nthy-ori 3-1 cells.
In our study, we observed that EGF treatment correlated with reduced miR-200 levels and EMT in Nthy-ori 3-1 cells (Fig. 3A) . To assess whether the miR-200 family regulates (Fig. 3A) . Furthermore, miR-200a/c re-expression resulted in increased E-cadherin expression (Fig. 3B ) and decreased vimentin expression (Fig. 3C) , thus reversing the mesenchymal phenotype of EGF-treated cells. (Fig. 4A) . Moreover, vimentin hypo-expression in EGFR-silenced cells was restored to basal levels following anti-miR-200 treatment (Fig. 4B) . Similarly, E-cadherin hyper-expression in EGFR-silenced cells was inhibited by anti-miR-200s treatment (Fig. 4C) .
EGFR siRNA-mediated MET induction is reversed by miR-200 family inhibition. We found that EGFR
EGF/EGFR regulation of thyroid cell EMT and invasion is reversed by miR-200s.
To analyze the miR-200 modulation of EGF-mediated EMT in thyroid cells, western blot analysis was performed to determine the expression of EMT protein markers. The re-expression of miR-200s in EGF-induced Nthy-ori 3-1 cells resulted in re-expression of E-cadherin and suppression of vimentin, whereas the suppression of miR-200s caused the downregulation of E-cadherin and the upregulation of vimentin in EGFR-silenced SW1736 cells (Fig. 5) . We investigated whether the EGF/EGFR regulation of the EMT process correlates with thyroid cancer cell invasion using a Matrigel invasion assay. In Nthy-ori 3-1 cells, EGF treatment resulted in increased cell invasion, which was inhibited by the re-expression of the miR-200s. Conversely, EGFR silencing inhibited SW1736 cell invasion, which was restored by the oligonucleotide suppression of miR-200s (Fig. 6) .
In vivo evaluation of miR-200 effects on MET in SW1736
xenografts. We analyzed the expression of E-cadherin and vimentin in SW1736 xenografts by immunohistochemistry. Mouse xenografts derived from SW1736 cells transfected with EGFR siRNA targeting showed strong membranous staining of E-cadherin and significantly lower vimentin expression (P<0.01, respectively). By contrast, xenografts derived from SW1736 cells co-transfected with anti-miR-200s and EGFR siRNA had E-cadherin and vimentin expression profiles similar to the xenografts from untransfected cells, indicating that the downregulation of miR-200s reverses the inhibitory effect of EGFR siRNA on EMT. Therefore, miR-200s play a crucial role in EGF/EGFR-mediated EMT in vivo (Fig. 7) .
Discussion
We report that EGF induction in thyroid cancer cells leads to the loss of miR-200 expression and increased Rho/ROCK activity, resulting in increased EMT and subsequent cancer invasion. Rho/ROCK is constitutively active in cancer cells and is therefore an attractive therapeutic target (22, 26) . Rho/ROCK activation is necessary for TGFβ-induced EMT, and inhibition of the Rho effector, ROCK, inhibits TGFβ-induced EMT in vitro and in vivo (27, 28) . In the current study, we observed increased Rho/ROCK activity in EGF-treated Nthy-ori 3-1 cells, and reduced Rho/ROCK activity in EGFR-silenced SW1736 cells.
Previous studies have indicated that EMT induction is regulated by the miR-200 family (18) (19) (20) (21) . TGFβ negatively regulates the expression of the miR-200 family and thereby promotes expression of zinc-finger enhancer binding (ZEB) transcription factors, leading to EMT in vitro (27) . In this study, we show that the re-expression of miR-200a/c by transfection of pre-miR-200 inhibits cell invasion in vitro, thus providing direct evidence in support of the involvement of miR-200s in EGF/EGFR-mediated effects on thyroid cancer cell aggressiveness. Using a reciprocal model in Nthy-ori 3-1 cells, we show that EGF-mediated cell invasion is effectively blocked by the re-expression of the miR-200s. Our in vitro and in vivo results indicate a key regulatory role for miR-200s in the modulation of EMT by EGF/EGFR.
Our current findings, together with existing literature, provide a model for EMT regulation by EGF/EGFR, miR-200s, Rho/ROCK and EMT markers (Fig. 8) . We therefore provide evidence for a mechanism linking the miR-200 family with EGF/EGFR signaling, suggesting that miR-200 upregulation may serve as a novel therapeutic strategy for highly invasive thyroid cancer. 
